Vivus, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (41)

Latest Posts

About This Stock More About This Stock
3 Biotech Stocks Up In The Past Month On Industry Turnaround
Article By: Zacks Investment Research
Tuesday, June 5, 2018 1:08 PM EST
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front.
In this article: BMRN, LGND, VVUS Also: JNJ
Qualcomm, Inc., VIVUS, Inc. Beat Earnings Estimates
Article By: ValueWalk
Wednesday, November 4, 2015 5:43 PM EST
Qualcomm reported adjusted earnings of 91 cents per share or $1.4 billion and $5.5 billion in revenue for its fourth fiscal quarter. Vivus posted losses of 15 cents per share and $24.9 million in revenues.
In this article: VVUS, QCOM
Shares Of Orexigen Soar After It Announces Improved Safety Results For Weight-Loss Drug
Article By: Terry Chrisomalis
Tuesday, March 3, 2015 2:37 PM EST
Orexigen's drug Contrave shows not only shows great safety but also shows the ability to reduce heart-related problems as compared to placebo.
In this article: OREX, ARNA, VVUS
VIVUS Q4 Loss Wider Than Expected, Qsymia Disappoints
Article By: Zacks Investment Research
Wednesday, February 25, 2015 11:56 AM EST
VIVUS Inc.’s fourth-quarter 2014 loss of 25 cents per share was wider than the Zacks Consensus Estimate loss by a penny and the year-ago loss of 9 cents.
In this article: VVUS
E Novo Nordisk's Saxenda Approved But Company Enters Into A Crowded Obesity Market
Article By: Terry Chrisomalis
Friday, December 26, 2014 3:58 PM EST
Saxenda Approved by the FDA to treat Obesity but faces big obstacles against many competitors.
In this article: NVO, TKPHF, OREX, ARNA, VVUS


Latest Tweets for $VVUS

No tweets yet!